fingolimod has been researched along with Allergic Encephalomyelitis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Beerli, C; Bergsdorf, C; Billich, A; Braendlin, N; Oberhauser, B; Schubart, A; Srinivas, H; Weiler, S | 1 |
| Balimane, P; Banas, D; Barrish, JC; Carter, PH; Cornelius, G; Cvijic, ME; D'Arienzo, C; Dyckman, AJ; Gillooly, K; Guo, J; Langevine, CM; Liu, R; Marino, A; McIntyre, KW; McKinnon, M; Moquin, RV; Pitts, WJ; Rex-Rabe, S; Salter-Cid, L; Shen, DR; Shuster, DJ; Spergel, SH; Suchard, SJ; Taylor, T; Warrack, B; Watterson, SH; Xie, J; Yarde, M | 1 |
| Balimane, P; Barrish, JC; Borowski, V; Carter, PH; Cornelius, G; Cvijic, ME; D'Arienzo, C; Dyckman, AJ; Galella, MA; Gillooly, K; Gilmore, JL; Haque, L; Levesque, PC; Li, JP; Marino, A; McIntyre, KW; Mukhopadhyay, P; Pitts, WJ; Salter-Cid, L; Shen, DR; Sheppeck, JE; Taylor, T; Tebben, AJ; Warrack, B; Watterson, SH; Xie, J; Yarde, M | 1 |
| Aronov, AM; Bandarage, UK; Cao, J; Chin, EY; Collier, PN; Come, JH; Damagnez, V; Davies, RJ; Deininger, D; Doran, JD; Dworakowski, W; Grey, R; Griffith, JP; Henderson, JA; Jacobs, MD; Khare-Pandit, S; Krueger, EB; Le Tiran, A; Liang, J; Liao, Y; Lowe, DB; Mahajan, S; Messersmith, D; Moody, CS; Nanthakumar, S; O'Dowd, H; Pierce, AC; Sizensky, E; Wang, J; Xu, J | 1 |
| Bankala, R; Doss, HM; Kapavarapu, RK; Kulkarni, P; Kumar, JS; Mathew, JE; Medishetti, R; Mudgal, J; Pal, M; Parsa, KVL; Ramarao, EVVS; Rasool, M; Shenoy, GG; Sunke, R; Thirupataiah, B | 1 |
| Bahn, YS; Cheong, E; Choi, JW; Hwang, H; Kim, B; Kim, HJ; Kim, J; Kim, JW; Kim, R; Kim, S; Kim, Y; Lee, EH; Lee, HY; Lee, J; Park, JH; Park, KD; Park, SJ; Seo, SH; Yeon, SK | 1 |
6 other study(ies) available for fingolimod and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
Topics: Administration, Oral; Aldehyde-Lyases; Animals; Catalytic Domain; Cells, Cultured; Crystallography, X-Ray; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Male; Models, Molecular; Multiple Sclerosis; Mutation; Phthalazines; Protein Conformation; Pyridines; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2014 |
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.
Topics: Animals; Arthritis, Experimental; Cell Movement; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppressive Agents; Isoxazoles; Lymphatic System; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Sphingosine; Structure-Activity Relationship; Thymus Gland | 2016 |
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).
Topics: Animals; Arthritis; Dogs; Encephalomyelitis, Autoimmune, Experimental; Ethanolamine; Female; Haplorhini; Humans; Lymphocyte Count; Lymphocytes; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2016 |
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Binding Sites; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Humans; Hydrogen Bonding; Isoenzymes; Mice, Inbred C57BL; Multiple Sclerosis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalimides; Structure-Activity Relationship | 2018 |
InCl
Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Experimental; Freund's Adjuvant; Indium; Indoles; Molecular Structure; Multiple Sclerosis; Oligodendrocyte-Myelin Glycoprotein; Phosphodiesterase 4 Inhibitors; Quinoxalines; Rats; Structure-Activity Relationship; Zebrafish; Zebrafish Proteins | 2019 |
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
Topics: Animals; beta-Arrestins; Dogs; Drug Design; Encephalomyelitis, Autoimmune, Experimental; Heart Rate; Humans; Isoxazoles; Lymphocyte Count; Lymphocytes; Male; Mice; Multiple Sclerosis; Rats; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Triazoles | 2022 |